NIH Researchers Identify Antibodies That Could Help Combat Alpha-Gal Syndrome

NIH Researchers Identify Rare Antibodies with Potential to Treat Tick-Related Alpha-Gal Syndrome

Researchers at the US National Institutes of Health have identified rare antibodies that could potentially contribute to future treatments for alpha-gal syndrome, an allergic condition associated with certain tick bites.

Alpha-gal syndrome can cause allergic reactions to alpha-gal, a sugar molecule found in red meat and other animal products. The condition can develop after bites from certain ticks and currently has no specific treatment or cure.

The discovery emerged unexpectedly from malaria research.

Scientists initially created 42 monoclonal antibodies against alpha-gal after studying people exposed to malaria. The original goal was to determine whether these antibodies could target alpha-gal molecules associated with malaria parasites.

When the antibodies did not perform as expected against the parasite, researchers investigated whether they might have another application.

They found that 13 of the antibodies were able to bind to allergens associated with alpha-gal syndrome.

Two antibodies were particularly notable because they blocked IgE antibodies from patients with alpha-gal syndrome from attaching to certain alpha-gal allergens.

One antibody also interfered with the activation of basophils, immune cells involved in allergic reactions.

The findings were published in the Journal of Clinical Investigation on September 1, 2026.

Alpha-gal syndrome is unusual among food allergies because reactions can involve products derived from mammals. Symptoms can occur after consuming red meat or other animal-derived products containing alpha-gal.

The condition is associated with tick exposure and has been reported increasingly in the United States and other parts of the world.

At present, management generally centres on avoiding foods and products that trigger allergic reactions and dealing with symptoms when reactions occur.

The newly identified antibodies could eventually provide another approach, but researchers stress that the work is still at an early stage.

The antibodies were identified and tested in laboratory settings. Additional research will be needed to determine whether they can safely prevent allergic reactions in people with alpha-gal syndrome.

The research also illustrates how scientific discoveries can emerge from unexpected connections.

The antibodies were originally developed as part of an investigation into malaria. Their ability to interact with alpha-gal-related allergens subsequently opened a possible pathway for research into a completely different condition.

Researchers will now need to investigate how these antibodies behave in more advanced experimental models and whether they could eventually become a usable medical treatment.

The development is therefore not a new treatment available to patients today. Instead, it represents an early research finding that could inform future approaches to an allergic condition for which treatment options remain limited.

The NIH said further studies are necessary to evaluate whether the antibodies could eventually be used to prevent allergic reactions in people with alpha-gal syndrome.

Source: National Institutes of Health.